Shattuck Labs (NASDAQ:STTK) Trading 5.5% Higher After Analyst Upgrade

Posted by Geri Gentry on Aug 26th, 2026

Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report)’s stock price shot up 5.5% during trading on Monday after Raymond James Financial upgraded the stock to a strong-buy rating. The company traded as high as $7.91 and last traded at $7.9450. 885,206 shares changed hands during mid-day trading, a decline of 1% from the average daily volume of 893,689 shares. The stock had previously closed at $7.53.

Other equities research analysts have also recently issued reports about the company. Leerink Partners initiated coverage on Shattuck Labs in a research note on Monday, July 20th. They set an “outperform” rating and a $16.00 price objective on the stock. HC Wainwright lowered their price objective on Shattuck Labs from $18.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Cantor Fitzgerald initiated coverage on Shattuck Labs in a report on Monday, April 27th. They issued an “overweight” rating for the company. TD Cowen raised Shattuck Labs to a “strong-buy” rating in a research report on Monday. Finally, Weiss Ratings upgraded Shattuck Labs from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.78.

Check Out Our Latest Analysis on STTK

Insider Buying and Selling

In related news, insider Arundathy N. Pandite sold 30,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $7.01, for a total value of $210,300.00. Following the sale, the insider directly owned 136,219 shares of the company’s stock, valued at $954,895.19. This represents a 18.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Clay B. Siegall acquired 62,500 shares of the firm’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average cost of $4.00 per share, with a total value of $250,000.00. Following the purchase, the director owned 318,608 shares of the company’s stock, valued at $1,274,432. The trade was a 24.40% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders sold 53,875 shares of company stock valued at $379,305. Company insiders own 8.79% of the company’s stock.

Institutional Investors Weigh In On Shattuck Labs

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System purchased a new position in Shattuck Labs during the 2nd quarter valued at $41,000. Frazier Life Sciences Management L.P. purchased a new stake in Shattuck Labs in the second quarter worth $26,025,000. Wellington Management Group LLP purchased a new stake in Shattuck Labs in the second quarter worth $12,269,000. Bank of America Corp DE bought a new stake in shares of Shattuck Labs during the second quarter worth $319,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Shattuck Labs during the second quarter worth $312,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Stock Up 2.0%

The stock has a market capitalization of $808.90 million, a PE ratio of -15.80 and a beta of 1.08. The stock’s 50 day moving average price is $6.89 and its 200-day moving average price is $6.15.

Shattuck Labs (NASDAQ:STTK – Get Free Report) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). As a group, sell-side analysts predict that Shattuck Labs, Inc. will post -0.43 earnings per share for the current fiscal year.

About Shattuck Labs

(Get Free Report)

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.